Showing 861 - 880 results of 885 for search '"Urals"', query time: 0.05s Refine Results
  1. 861
  2. 862

    The rate of eye comorbidities in patients with cataracts (results of a population study) by M.M. Bikbov, O.I. Orenburkina, T.R. Gilmanshin, A.E. Babushkin

    Published 2023-08-01
    “…Babushkin<sup>1</sup> </p> <p> <sup><br> </sup> </p> <p> <sup>1</sup>Ufa Research Institute of Eye Diseases of the Bashkir State Medical University, Ufa, Russian Federation </p> <p> <sup>2</sup>Russian Center for Eye and Plastic Surgery of Eye Diseases of the Bashkir State Medical University, Ufa, Russian Federation </p> <p> <b>Aim: </b>to assess the prevalence and characteristics of various types of cataracts and to analyze most common eye comorbidities from the population study "Ural Eye and Medical Study" (UEMS). </p> <p> <b>Patients and Methods: </b>this population study included 5899 individuals (3400 living in the rural area and 2499 living in the city). …”
    Get full text
    Article
  3. 863
  4. 864
  5. 865
  6. 866
  7. 867
  8. 868
  9. 869

    Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma by D.A. Dorofeev, V.P. Balukhtina, M.V. Es’kova, K.A. Efimova, E.V. Kirilik, K.O. Luk’yanova

    Published 2021-09-01
    “…&nbsp;Luk’yanova<sup>1</sup></b> </p> <p> <b><sup>1</sup>City Clinical Hospital No. 2, Polyclinic № 1, Chelyabinsk, Russian Federation</b> </p> <p> <b><sup>2</sup>South Ural State Medical University, Chelyabinsk, Russian Federation</b> </p> <p> <i><b>Aim</b>: to evaluate additive IOP-lowering effect of brimonidine 0.2% to achieve target IOP via enhancing maximum tolerated medical therapy for primary open-angle glaucoma (POAG).…”
    Get full text
    Article
  10. 870
  11. 871
  12. 872
  13. 873
  14. 874
  15. 875
  16. 876
  17. 877
  18. 878
  19. 879
  20. 880